The association of inflammatory and fibrinolytic proteins with 5 year change in insulin clearance: The Insulin Resistance Atherosclerosis Study (IRAS)

Diabetologia

Volumn 56, Issue 1, 2013, Pages 112-120

  Lee, C C ^a   Lorenzo, C ^b   Haffner, S M ^c   Wagenknecht, L E ^d   Festa, A ^e   Goodarzi, M O ^f   Stefanovski, D ^f   Olson, N C ^g   Norris, J M ^h   Rewers, M J ⁱ   Hanley, A J ^a,j,k  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d WAKE FOREST SCHOOL OF MEDICINE   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

^g UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^h Global Health and Health Disparities   (United States)

ⁱ UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF TORONTO   (Canada)

^k MOUNT SINAI HOSPITAL   (Canada)

more..

Author keywords

C reactive protein; Fibrinogen; Leptin; Metabolic clearance of insulin; Plasminogen activator inhibitor 1; TNF

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AFRICAN AMERICAN; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CAUCASIAN; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNIC DIFFERENCE; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; FOLLOW UP; GLUCOSE BLOOD LEVEL; HISPANIC; HUMAN; INFLAMMATION; INSULIN CLEARANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC CLEARANCE RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; WAIST CIRCUMFERENCE;

ATHEROSCLEROSIS; BODY MASS INDEX; COHORT STUDIES; DIABETIC ANGIOPATHIES; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; LEPTIN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; OVERWEIGHT; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDIABETIC STATE; PROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 84871622464     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2741-8     Document Type: Article

References (50)

1. Meigs JB (2000) Insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 152:908-911
2. Chan JC, Tong PC, Critchley JA (2002) The insulin resistance syndrome: mechanisms of clustering of cardiovascular risk. Semin Vasc Med 2:45-57
3. Mittelman SD, van Citters GW, Kim SP et al. (2005) Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced beta-cell response. Diabetes 49:2116-2125
4. Pickup JC, Crook MA (1998) Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241-1248 (Pubitemid 28449093)
5. Trost S, Pratley R, Sobel B (2006) Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes. Curr Diab Rep 6:47-54
6. Festa A, D'Agostino R, Tracy RP, Haffner SM (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes. The Insulin Resistance Atherosclerosis Study. Diabetes 51:1131-1137 (Pubitemid 34438360)
7. Lee CC, Adler AI, Sandhu MS et al. (2009) Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia 52:1040-1047
8. Gkrania-Klotsas E, Ye Z, Cooper AJ et al. (2010) Differential white blood cell count and type 2 diabetes: systematic review and meta-analysis of cross-sectional and prospective studies. PLoS One 5:e13405
9. Festa A, D'Agostino R, Howard G et al. (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome. Circulation 102:42-47
10. Haffner SM, Mykkanen L, Rainwater DL, Karhapaa P, Laakso M (1999) Is leptin concentration associated with the insulin resistance syndrome in nondiabetic men? Obes Res 7:164-169 (Pubitemid 129710574)
11. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP (2000) Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 152:897-907
12. Wagenknecht LE, Mayer EJ, Rewers M et al. (1995) The Insulin Resistance Atherosclerosis Study (IRAS) objectives, design, and recruitment results. Ann Epidemiol 5:464-472
13. Bergman RN, Finegood DT, Ader M et al. (1985) Assessment of insulin sensitivity in vivo. Endocrine Rev 6:45-86
14. Welch S, Gebhart SS, Bergman RN, Phillips LS (1990) Minimal model analysis of intravenous glucose tolerance test derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab 71:1508-1518 (Pubitemid 120032768)
15. Steil GM, Volund A, Kahn SE, Bergman RN (1993) Reduced sample number for calculation of insulin sensitivity and glucose effectiveness from the minimal model: suitability for use in population studies. Diabetes 42:250-256 (Pubitemid 23045028)
16. Lorenzo C, Wagenknecht LE, D'Agostino RB Jr et al. (2010) Insulin resistance, beta-cell dysfunction, and conversion to type 2 diabetes in multiethnic population: the Insulin Resistance Atherosclerosis Study. Diabetes Care 33:67-72
17. Polonsky KS, Pugh W, Jaspan JB et al. (1984) C-peptide and insulin secretion. Relationship between peripheral concentrations of C-peptide and insulin and their section rates in the dog. J Clin Invest 74:1821-1829 (Pubitemid 15214096)
18. Declerck P, Collen D (1990) Measurement of plasminogen activator inhibitor 1 (PAI-1) in plasma with various monoclonal antibody-based enzyme-linked immunosorbent assays. Thromb Res 10(Suppl):3-9 (Pubitemid 20091388)
19. Macy E, Hayes T, Tracy R (1997) Variability in the measurement of C-reactive protein in healthy subjects: implications for reference interval and epidemiological applications. Clin Chem 43:52-58 (Pubitemid 27024390)
20. Clauss A (1957) Rapid physiological coagulation method for the determination of fibrinogen. Acta Haematol 17:237-246
21. Geffken D, Keating F, Kennedy M et al. (1994) The measurement of fibrinogen in population-based research: studies on instrumentation and methodology. Arch Pathol Lab Med 118:1106-1109 (Pubitemid 24345834)
22. Lorenzo C, Nath SD, Hanley AJ, Abboud HE, Haffner SM (2008) Relation of low glomerular filtration rate to metabolic disorders in individuals without diabetes and with normoalbuminuria. Clin J Am Soc Nephrol 3:783-789
23. Olson NC, Callas PW, Hanley AJ et al. (2012) Circulating levels of TNF-α are associated with impaired glucose tolerance, increased insulin resistance, and ethnicity: the Insulin Resistance Atherosclerosis Study. J Clin Endocrinol Metab 97:1032-1040
24. Howard BV, Mayer-Davis EJ, Goff D et al. (1998) Relationships between insulin resistance and lipoproteins in nondiabetic African Americans, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Metabolism 47:1174-1179 (Pubitemid 28469240)
25. Wagenknecht LE, Palmer ND, Bowden DW et al. (2011) Association of PNPLA3 with non-alcoholic fatty liver disease in a minority cohort: the Insulin Resistance Atherosclerosis Family Study. Liver Int 31:412-416
26. Juhan-Vague I, Alessi MC, Mavri A, Morange PE (2003) Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 1:1575-1579
27. Festa A, D'Agostino R Jr, Mykkanen L et al. (1999) Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in large population with different states of glucose tolerance: the Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 19:562-568 (Pubitemid 29135156)
28. Festa A, Williams K, Tracy RP, Wagenknecht LE, Haffner SM (2006) Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 113:1753-1759 (Pubitemid 43958468)
29. Lee KW, Lip GY (2003) Effects of lifestyle on hemostasis, fibrinolysis and platelet reactivity: a systematic review. Arch Intern Med 163:2368-2392 (Pubitemid 37310199)
30. Nagi DK, Yudkin JS (1993) Effects of metformin on insulin resistance, risk factors for cardiovascular disease and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 16:621-629 (Pubitemid 23097212)
31. Fonseca VA, Reynolds T, Hemphill D et al. (1998) Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 12:181-186 (Pubitemid 28284746)
32. Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS (1993) Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycemic control. Diabet Med 10:27-32 (Pubitemid 23089100)
33. Eliasson MC, Jansson JH, Lindahl B, Stegmayr B (2003) High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA study. Cardiovasc Diabetol 2:19 (Pubitemid 38751094)
34. Savvidou M, Nelson SM, Makgoba M et al. (2010) First-trimester prediction of gestational diabetes mellitus: examining the potential of combining maternal characteristics and laboratory measures. Diabetes 59:3017-3022
35. Duckworth WC, Bennett RG, Hamel FG (1998) Insulin degradation: progress and potential. Endocr Rev 19:608-624 (Pubitemid 28467714)
36. Inoue K, Sugawara Y, Kubota K, Takayama T, Makuuchi M (2000) Induction of type I plasminogen activator inhibitor in human liver ischemia and reperfusion. J Hepatol 33:407-414 (Pubitemid 30663378)
37. de Larrañaga G, Wingeyer SP, Graffigna M et al. (2008) Plasma plasminogen activator inhibitor-1 levels and nonalcoholic fatty liver in individuals with features of metabolic syndrome. Clin Appl Thromb Hemost 14:319-324 (Pubitemid 351871935)
38. Brunner EJ, Kivimaki M, Witte DR et al. (2008) Inflammation, insulin resistance and diabetes - Mendelian randomization using CRP haplotypes points upstream. PLoS Med 5(8):e155
39. Flier JS, Minaker KL, Landsberg L et al. (1982) Impaired in vivo insulin clearance in patients with severe target-cell resistance to insulin. Diabetes 31:132-135 (Pubitemid 12223964)
40. Cawthorn WP, Sethi JK (2008) TNF-alpha and adipocyte biology. FEBS Lett 582:117-131 (Pubitemid 350297248)
41. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95:2409-2415
42. Chen X, Xun K, Chen L, Wang Y (2009) TNF-alpha, a potent lipid metabolism regulator. Cell Biochem Funct 27:407-416
43. Laakso M, Sarlund H, Mykkänen L (1990) Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance. Arteriosclerosis 10:223-231 (Pubitemid 20103584)
44. Plomgaard P, Nielsen AR, Fischer CP et al. (2007) Associations between insulin resistance and TNF-alpha in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes. Diabetologia 50:2562-2571 (Pubitemid 350060651)
45. Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548-2556 (Pubitemid 38766330)
46. Pickup JC, Chusney GD, Mattock MB (2000) The innate immune response and type 2 diabetes: evidence that leptin is associated with a stress-related (acute-phase) reaction. Clin Endocrinol (Oxf) 52:107-112 (Pubitemid 30108292)
47. Liew CF, Seah ES, Yeo KP, Lee KO, Wise SD (2003) Lean, nondiabetic Asian Indians have decreased insulin sensitivity and insulin clearance, and raised leptin compared to Caucasians and Chinese subjects. Int J Obes 27:784-789 (Pubitemid 36819534)
48. Goodarzi MO, Taylor KD, Guo X et al. (2005) Variation in the gene for muscle-specific AMP deaminase is associated with insulin clearance, a highly heritable trait. Diabetes 54:1222-1227 (Pubitemid 40446340)
49. Mohamed-Ali V, Gould MM, Gillies S et al. (1995) Association of proinsulin-like molecules with lipids and fibrinogen in non-diabetic subjects: evidence against a modulating role for insulin. Diabetologia 38:1110-1116
50. Bertom AG, Burke G, Owusu JA et al. (2010) Inflammation and the incidence of type 2 diabetes. The Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 33:804-810